COMPARISON OF PEMETREXED PLUS CISPLATIN WITH OTHER FIRST-LINE DOUBLETS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A COMBINED ANALYSIS OF THREE PHASE 3 TRIALS

被引：0
|
作者：
Treat, Joseph [1 ]
Scagliotti, Giorgio [2 ]
Peng, Guangbin [1 ]
Pohl, Gerhardt [1 ]
Obasaju, Coleman [1 ]
机构：
[1] Eli Lilly & Co, Med, Indianapolis, IN USA
[2] Univ Turin, S Luigi Hosp, Dept Clin & Biol Sci, I-10124 Turin, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
NSCLC; Pemetrexed;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S415 / S416
页数：2
相关论文
共 50 条
  • [31] Systematic analysis of design and stratification for phase III trials in first-line advanced non-small cell lung cancer
    Komiya, Takefumi
    Perez, Raymond P.
    Erickson, Kirsten D.
    Huang, Chao H.
    [J]. THORACIC CANCER, 2016, 7 (01) : 66 - 71
  • [32] Economic analysis of TORCH: Erlotinib versus cisplatin and gemcitabine as first-line therapy for advanced non-small cell lung cancer (NSCLC).
    Chung, Carmen
    Isaranuwatchai, Wanrudee
    Di Maio, Massimo
    Jiang, Haiyan
    Lau, Anthea
    Hoch, Jeffrey S.
    Feld, Ronald
    Tsao, Ming Sound
    Gridelli, Cesare
    Ciardiello, Fortunato
    Butts, Charles Andrew
    Gallo, Ciro
    Perrone, Francesco
    Leighl, Natasha B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] ECONOMIC ANALYSIS OF TORCH: ERLOTINIB VERSUS CISPLATIN AND GEMCITABINE AS FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Chung, Carmen
    Jiang, Haiyan
    Isaranuwatchai, Wanrudee
    Di Maio, Mas-Simo
    Lau, Anthea
    Hoch, Jeffrey
    Feld, Ronald
    Tsao, Ming-Sound
    Gridelli, Cesare
    Gallo, Ciro
    Ciardiello, Fortunato
    Butts, Charles A.
    Perrone, Francesco
    Leighl, Natasha B.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S602 - S603
  • [34] Docetaxel (Taxotere®) as first-line therapy of advanced non-small cell lung cancer (NSCLC)
    Manegold, C
    [J]. ONKOLOGIE, 2003, 26 : 26 - 32
  • [35] PALLIATIVE RADIATION DURING PEMETREXED PLUS CISPLATIN FIRST-LINE TREATMENT OR PEMETREXED CONTINUATION MAINTENANCE TREATMENT IN ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A REPORT OF PATIENT SAFETY IN THE PARAMOUNT TRIAL
    De Marinis, Filippo
    Gridelli, Cesare
    Dediu, Mircea
    Thomas, Michael
    Pujol, Jean-Lois
    Molinier, Olivier
    Reck, Martin
    Sahoo, Tarini P.
    San Antonio, Belen
    John, William J.
    Zimmermann, Annamaria H.
    Chouaki, Nadia
    Visseren-Grul, Carla
    Paz-Arez, Luis G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S842 - S843
  • [36] Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Scagliotti, Giorgio
    Purvish, Parikh
    von Pawel, Joachim
    Biesma, Bonna
    Vansteenkiste, Johan
    Manegold, Christian
    Simms, Lorinda
    Posther, Sugarman Katherine
    Obasaju, Coleman
    Blatter, Johannes
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S306 - S306
  • [37] Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Manegold, C.
    Digumarti, R.
    Zukin, M.
    de Marinis, F.
    Mellerngaard, A.
    Gandara, D.
    Simms, L.
    Kaiser, C.
    Blatter, J.
    Gatzemeier, U.
    [J]. EJC SUPPLEMENTS, 2007, 5 (06): : 9 - 9
  • [38] Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial
    Gervais, Radj
    Robinet, Gilles
    Clement-Duchene, Christelle
    Denis, Fabrice
    El Kouri, Claude
    Martin, Philippe
    Chouaki, Nadia
    Bourayou, Nawel
    Morere, Jean-Francois
    [J]. LUNG CANCER, 2013, 80 (02) : 185 - 190
  • [39] Gemcitabine plus cisplatin in advanced non-small cell lung cancer (NSCLC): A phase II study
    Orlandi-Jorquera, L
    Orlandi, F
    Galaz, P
    Gamargo, C
    Salman, P
    Yanez, M
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 101 - 101
  • [40] Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer a multicenter, randomized, phase II trial
    Scagliotti, GV
    Kortsik, C
    Dark, GG
    Price, A
    Manegold, C
    Rosell, R
    O'Brien, M
    Peterson, PM
    Castellano, D
    Selvaggi, G
    Novello, S
    Blatter, J
    Kayitalire, L
    Crino, L
    Paz-Ares, L
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (02) : 690 - 696
12345